Dr. Foster brings over 30 years of pharmaceutical and biotech experience to Contravir. Prior to Contravir, he was CEO and Founder of Ciclofilin Pharmaceuticals Inc. which merged with ContraVir. Prior to Ciclofilin Pharmaceuticals, he founded Isotechnika Pharma Inc. He was Chairman and CEO of Isotechnika (TSX:ISA) for 21 years. Dr. Foster was founding CEO, and later CSO, of Aurinia (NASDAQ:AUPH) after Isotechnika acquired Aurinia. During his tenure with Isotechnika, Dr. Foster, together with a core team, discovered the immunosuppressive drug voclosporin. In 2002, while Isotechnika’s CEO, Dr. Foster structured Canada’s largest licensing deal, at the time, for $215 million USD with Hoffman-La Roche (Basle, Switzerland) for voclosporin. In addition to pharmaceutical discovery and development, Dr. Foster also developed and obtained regulatory approvals for a commercially available diagnostic test (carbon-13 urea breath test), called Helikit, for the diagnosis of H. pylori. After realizing multimillion dollar commercial sales, Dr. Foster subsequently sold the diagnostic kit. At present, Helikit sales continue in Canada and other countries.

Dr. Foster is currently Professor, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, and is currently a Board member of Transcriptome Sciences Inc.He has previously served as Board member for Alberta Economic Development Authority, Business Competitiveness and Diversification Committee; Board member of Alberta Economic Development, Fiscal Planning and Policy Committee; Council Member, Alberta Premier’s Advisory Council on Health; Advisory Board Member, Industry Liason Office, University of Alberta; Co-Chair and Board member of BioAlberta; and Board of Management, Alberta Science and Research Authority.

After graduating with a Ph.D. in Pharmaceutical Sciences, Dr. Foster served as a tenured, Associate Professor in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta (1988 to 1997). From 1998 to 2001, Dr. Foster served as an Adjunct Full Professor at the same university. From 1990 to 1994, Dr. Foster was Medical Staff, Scientific and Research Associate in the Department of Laboratory Medicine at the Walter C. MacKenzie Health Sciences Centre. He has published over 170 papers, abstracts and book chapters focused on drug analysis, development, and pharmacokinetics, and received numerous awards for both pharmaceutical research and teaching. Dr. Foster was also named Alberta’s 50 Most Influential People in 2002, and received Alberta Venture’s 3rd Fastest Growing Company, 2003, for Isotechnika, as well as being named amongst the top 100 Fastest Growing Canadian Company by Profit Magazine in 2003. Dr. Foster previously served as Division Chairman of Pharmacy Practice at the University of Alberta, and has acted as a consultant to many pharmaceutical companies. Dr. Foster is named as an inventor on 242 patents, of which 216 are currently active and granted, 5 allowed, and 21 that are pending. Dr. Foster serves as an Honorary Professor on the Faculty of Pharmacy & Pharmaceutical Sciences at the University of Alberta.